Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advance
Go back to Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advance| Johnson & Johnson (NYSE: JNJ) | Delayed: 269.47 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $269.47 | 52 Week High | $126.07 | |||
| Open | $269.47 | 52 Week Low | $94.28 | |||
| Day High | $269.47 | P/E | 56.02 | |||
| Day Low | $269.47 | EPS | $4.81 | |||
| Volume | 1,112 | |||||
